Prognostic significance of @entity1722 oncoprotein expression in XXXX . The influence of the pattern of immunostaining and adjuvant therapy.

@entity1 @entity172 @entity10815 @entity2007 @entity0 @entity1420 @entity2284 @entity5 @entity406 @entity982 @entity1722
BACKGROUND: The influence of @entity1722 on prognosis of @entity0 is controversial. The authors investigated by immunohistochemistry in node-positive disease the influence of the pattern of immunostaining (membranous or cytoplasmic) on outcome and the prognostic significance of this marker in @entity1 receiving or not receiving adjuvant therapy. METHODS: The immunostaining for @entity1722 oncoprotein was performed on @entity406 -solution-fixed, @entity982 -embedded sections of 888 node-positive @entity0 resected between 1980 and 1986 and for which a follow-up of 2.5-10.5 years was available. The staining was performed using a polyclonal antibody (dilution, 1/15). RESULTS: One hundred forty-three cases (16.1%) revealed a positive membrane staining with or without additional cytoplasmic contribution, whereas cytoplasmic staining alone was noted in 118 cases (13.3%). Positive membrane staining was correlated with more involved lymph nodes (P = 0.005), @entity2007 (P = 0.002), poor nuclear (P < 0.0001) and histologic (P = 0.007) grades, absence of @entity172 (P < 0.0001) and @entity1420 (P < 0.0001) receptor content, and @entity10815 expression (P = 0.009). No relation was found (P > 0.05) with either age, @entity5 size, or @entity2284 expression. Membrane staining was strongly associated with poor distant metastasis-free or overall survival rate (P < 0.0001), whereas cytoplasmic staining had no prognostic significance. Two hundred thirty-two @entity1 (26.1%) received no additional treatment after surgery. The difference in survival rates between cases with positive and negative staining was only significant among @entity1 submitted to adjuvant chemotherapy or hormone therapy. CONCLUSIONS: This study strongly supports the association of @entity1722 oncoprotein expression with poor prognosis in @entity0 and demonstrates that membranous but not cytoplasmic staining is prognostically relevant. It also shows that @entity1722 oncoprotein expression is useful in predicting survival time only in @entity1 receiving adjuvant therapy, thus suggesting that it may be a marker of drug resistance.
